Drug
Pegpleranib sodium clinical trials
Also written E10030 and Fovista®.
How studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 2
Ophthotech Corporation (6) · National Eye Institute (NEI) (1) · Retinal Consultants of Arizona (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses pegpleranib sodium is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® MonotherapyTerminatedPhase 3Ophthotech CorporationNCT01940887Written as E10030
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedPhase 3Ophthotech CorporationNCT01940900Written as E10030
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedPhase 3Ophthotech CorporationNCT01944839Written as E10030
- A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular DegenerationCompletedPhase 2Ophthotech CorporationNCT01089517Written as E10030 plus Lucentis
- Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMDTerminatedPhase 2Ophthotech CorporationNCT02214628Written as Fovista® (anti-PDGF BB) plus anti-VEGF
- A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular DegenerationCompletedPhase 1Ophthotech CorporationNCT00569140Written as E10030
- A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist RanibizumabCompletedPhase 1/2National Eye Institute (NEI)NCT02859441Written as E10030
- An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular DegenerationCompletedPhase 1Retinal Consultants of ArizonaNCT02591914Written as Fovista™
Given in every arm · 1 — pegpleranib sodium is usual care beside what is tested
Codes
What other systems call pegpleranib sodium · ClinicalTrials.gg INT016322
- UNII (FDA) DD50D2QKH1PEGPLERANIB SODIUMOne source FDA
- NCI Thesaurus C170304Pegpleranib SodiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DD50D2QKH1 | PEGPLERANIB SODIUM | One source FDA |
| NCI Thesaurus | C170304 | Pegpleranib Sodium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.